Evobrutinib - Merck Serono

Drug Profile

Evobrutinib - Merck Serono

Alternative Names: M-2951; MSC 2364447; MSC2364447C

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Class Antirheumatics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Phase I Autoimmune disorders
  • Preclinical Encephalomyelitis

Most Recent Events

  • 21 Mar 2018 Merck KGaA initiates enrolment in a phase I trial in volunteers in Germany (NCT03436394)
  • 07 Mar 2018 Evobrutinib is still in phase I trials for Autoimmune-disorders (In volunteers) in Germany
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top